- Home
- CYCN vs AYTU Comparison
CYCN vs AYTU Comparison
Compare CYCN & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- AYTU
- Stock Information
- Founded
- CYCN 2018
- AYTU N/A
- Country
- CYCN United States
- AYTU United States
- Employees
- CYCN N/A
- AYTU N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- CYCN Health Care
- AYTU Health Care
- Exchange
- CYCN Nasdaq
- AYTU Nasdaq
- Market Cap
- CYCN 11.8M
- AYTU 9.6M
- IPO Year
- CYCN N/A
- AYTU N/A
- Fundamental
- Price
- CYCN $2.17
- AYTU $2.24
- Analyst Decision
- CYCN
- AYTU Strong Buy
- Analyst Count
- CYCN 0
- AYTU 2
- Target Price
- CYCN N/A
- AYTU $10.00
- AVG Volume (30 Days)
- CYCN 58.6K
- AYTU 151.5K
- Earning Date
- CYCN 08-05-2025
- AYTU 09-25-2025
- Dividend Yield
- CYCN N/A
- AYTU N/A
- EPS Growth
- CYCN N/A
- AYTU N/A
- EPS
- CYCN N/A
- AYTU N/A
- Revenue
- CYCN $2,174,000.00
- AYTU $81,659,000.00
- Revenue This Year
- CYCN N/A
- AYTU N/A
- Revenue Next Year
- CYCN N/A
- AYTU $1.05
- P/E Ratio
- CYCN N/A
- AYTU N/A
- Revenue Growth
- CYCN N/A
- AYTU 0.41
- 52 Week Low
- CYCN $1.27
- AYTU $0.95
- 52 Week High
- CYCN $9.47
- AYTU $2.85
- Technical
- Relative Strength Index (RSI)
- CYCN 32.29
- AYTU 43.26
- Support Level
- CYCN $2.51
- AYTU $2.30
- Resistance Level
- CYCN $2.41
- AYTU $2.82
- Average True Range (ATR)
- CYCN 0.25
- AYTU 0.16
- MACD
- CYCN -0.07
- AYTU -0.05
- Stochastic Oscillator
- CYCN 3.48
- AYTU 6.45
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.